广州安必平医药科技股份有限公司股东减持股份计划公告

Core Viewpoint - The announcement details a share reduction plan by a major shareholder of Guangzhou Anbiping Pharmaceutical Technology Co., Ltd., due to funding needs, which may impact the company's stock performance and investor sentiment [3][9]. Shareholder Holding Situation - As of the announcement date, Nanjing Qianjing Venture Capital Partnership holds 1,677,265 shares, representing 1.79% of the total share capital of the company [2]. Reduction Plan Details - Nanjing Qianjing plans to reduce its holdings by up to 1,677,265 shares, with a maximum of 935,676 shares through centralized bidding and 741,589 shares via block trading, within three months after the announcement [3][6]. - The reduction will commence 15 trading days after the announcement [3]. Shareholder's Past Reduction Activities - Nanjing Qianjing is required to disclose reduction plans only if its holdings fall below 5% [5]. Compliance and Commitments - The shareholder has made commitments regarding the holding period and reduction methods, including not selling shares during the lock-up period and ensuring that any reduction price does not fall below the adjusted issue price [7][8]. - The company will adhere to relevant regulations and timely disclose information regarding the reduction [9].